摘要
目的建立RP-HPLC测定大鼠血浆中葛根素浓度的方法,研究葛根提取物及复方脑得生片中葛根素的药动学特点,评价复方中其他配伍对葛根素药动学的影响。方法大鼠分别灌胃给予葛根提取物、复方脑得生片,断尾采血,离心,取血浆适量,加甲醇沉淀蛋白,取上清液过滤,用HPLC分析,以C18为固定相,流动相为甲醇-0.5%醋酸水溶液(25∶75),在250nm下检测,测定葛根素血药浓度,经3P97软件处理数据。结果葛根素血浆浓度在10~1000μg·L-1之间线性关系良好,最低检测浓度为6μg·L-1,高,中,低浓度样品回收率分别为89.9%,95.5%,89.7%。大鼠灌胃葛根提取物和脑得生片后的药-时曲线均符合二房室模型。灌胃脑得生片后,与灌胃葛根提取物相比,前者测定的葛根素ρmax和AUC0→∞分别比后者增加了2.23和3.03倍。结论本实验建立的RP-HPLC测定法专属、准确、灵敏,适用于葛根提取物及复方脑得生中葛根素的药动学研究。研究结果表明,脑得生片中的其他配伍药材可以促进葛根素的吸收,提高葛根素的生物利用度。
Abstract
OBJECTIVE To develop a RP-HPLC method for the determination of the concentration of puerarin in rat plasma,to study the pharmacokinetics of pueraria extradite and Naodesheng tablet,and to investigate the effect of other components in compound on the pharmacokinetics of puerarin.METHODS The rats received 100 mg·kg-1 pueraria extract and Naodesheng tablet by oral administration.After liquide extraction with methanol,plasma concentration of puerarin was measured.The pharmacokinetic parameters were calculated with 3P97 program.RESULTS A good linear relationship of puerarin was obtained in the range of 10 and 1 000 μg·L-1,the lowest limit of determination was 6 μg·L-1.The mean recoveries were 89.9%,95.5%,89.7% for high,middle,low concentrations of the samples respectively.The plasma concentration-time curves of puerarin were fitted with two-compartments model.The AUC0→∞ and ρmax of puerarin were increased in the Naodesheng group,compared with 100 mg·kg-1 pueraria extract group.CONCLUSION The HPLC method was selective,accurate and sensitive.The results indicated that the other herbs improved the absorption of puerarin and increased the bioavailability of puerarin significantly.
关键词
葛根素 /
脑得生片 /
药动学 /
高效液相色谱法
{{custom_keyword}} /
Key words
puerarin /
Naodesheng tablet /
pharmacokinetics /
HPLC
{{custom_keyword}} /
潘璐琳;欧阳臻;杨雨;汤建明;王博.
葛根及复方中葛根素在大鼠体内的药动学研究[J]. 中国药学杂志, 2009, 44(09): 703-705
PN Lu-lin;OUYNG Zhen;YNG Yu;TNG Jin-ming;WNG o.
Pharmacokinetics of Puerarin in Pueraria and Its Compound Preparation in Rat [J]. Chinese Pharmaceutical Journal, 2009, 44(09): 703-705
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Ch.P(2005)Vol ?(中国药典2005年版.一部)[S].2005:572.
[2] YAO D,DING X S.Discussions in pharmacological action and the development in clinical application of puerarin[J].Chin J Clin Pharmacol Therapeutics(中国临床药理学与治疗学),2008,13(4):468-471.
[3] ZHANG Z R,YOU X J,WEI Z P,et al. Pharmacokinetics and bioavailability of Yufeng Ningxin Jiaonang in rabbits[J]. Chin Pharm J (中国药学杂志),1997,32(4):224-226.
[4] JIN X L,ZHU X Y. Pharmacokinetics of puerain in rats,rabbits,and dogs[J]. Acta Pharmacol Sin(中国药理学报),1992,13(3):284-288.
[5] XIANG D X,ZHANG J,LI H D,et al. HPLC Determination of puerarine in dog plasma[J].Chin J Pharm Anal(药物分析杂志),2004,24(6):599-601.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
江苏大学高级专业人才科研启动基金(06JDG042)
{{custom_fund}}